Xbrane Biopharma presenterar vid Stora Aktiedagen den 28 november i Stockholm

Xbrane Biopharma kommer att presentera vid investerarkonferensen Stora Aktiedagen, arrangerat av Aktiespararna, den 28 november i Stockholm, Sverige.

Företagets presentation kommer att äga rum kl.12:50. Xbrane kommer att representeras av Vd Martin Åmark och operativ chef Siavash Bashiri, som under  (…)

Xbrane Biopharma to present at Stora Aktiedagen on November 28 in Stockholm

Xbrane Biopharma will present at the investor conference Stora Aktiedagen, arranged by the Swedish Shareholders’ Association, Aktiespararna, on November 28 in Stockholm, Sweden.

The company’s presentation will take place at 12:50 pm. Xbrane will be represented by CEO Martin Åmark and COO Siavash Ba (…)

Xbrane Biopharma AB (publ) releases interim report for the period July - September 2016

Xbrane  Biopharma  ABs  interim  report  for  the  period July – September 2016 is now available on the Company’s website, www.xbrane.com.

Period July – September 2016

• Group net sales amounted to SEK 71 840 (129 988)
• Group total income amounted to SEK 137 570  (…)

Xbrane Biopharma AB (publ) publicerar delårsrapport för perioden juli - september 2016

Xbrane Biopharma ABs delårsrapport för perioden juli – september 2016 finns från och med idag tillgänglig på bolagets webbsida, www.xbrane.com

Perioden juli – september 2016

• Koncernens nettoomsättning uppgick till 71 840 (129 988) SEK
• Koncernens totala intäkter uppgick till 137 570 (136 884) S (…)

Analyst coverage on Xbrane Biopharma

In accordance with the communicated statement in our previous shareholder letter, we inform that the Xbrane share is being analysed by the international research house Edison, which has issued a initial short abstract “quick view” to be followed by a full initiating coverage before the years end. Ed (…)

Xbrane signs term-sheet for distribution of Spherotide in China generating approx. SEK 70 M in revenue until market approval and expected sales of SEK 350 M annually for Xbrane and the Chinese partner

Press release
2016-11-01
  
Xbrane Biopharma has signed a non-binding term sheet with a leading Chinese pharmaceutical company regarding the distribution of Spherotide in the Chinese market. The commercial terms are negotiated and the intended transaction will give the Chinese company exclusi (…)

Xbrane Biopharma AB ("Xbrane") has received scientific advice regarding regulatory and clinical aspects of the planned submission of a Marketing Authorization Application (MAA) for Spherotide in EU

Press release
2016-10-31

Xbrane has received advice from BfArM, the German Federal Institute for Drugs and Medical Devices, with regards to the clinical and regulatory aspects of the Company’s planned submission of a Marketing Authorization Application (MAA) for Spherotide 1-month formulation for  (…)

Change in number of shares and votes in Xbrane Biopharma

Press release
2016-10-31

Xbrane Biopharma AB (publ) (“The Company”) has, according to previously published information, converted 10% of the outstanding convertible into shares in conjunction with the achievement of the first milestone related to the development of Spherotide.

Hence, the total nu (…)